Immunotherapy is fastest growing segment fueling the growth of pancreatic cancer therapeutics and diagnostics market
Global Pancreatic Cancer Therapeutics and Diagnostic Market |
The global pancreatic cancer
therapeutics and diagnostic market is estimated to be valued at US$ 4255.87 Mn in 2023 and is expected
to exhibit a CAGR of 7.4% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market Overview:
Pancreatic cancer is a type of
cancer that develops in the pancreas, a gland located behind the stomach and
next to the small intestine and liver. Pancreatic cancer therapies and
diagnostics play an important role in early detection and treatment.
Therapeutic and diagnostic options help in improving the survival rate and
quality of life of patients.
Market key trends:
One of the key trends driving the
pancreatic cancer therapeutics and diagnostic market is the rising number of
immunotherapy approvals. Immunotherapy is emerging as a promising treatment
option and several immunotherapy drugs have been approved or are under clinical
trials. For instance, Opdivo (nivolumab), which is an immune checkpoint
inhibitor, was approved by the FDA in 2017 for metastatic pancreatic cancer
previously treated with gemcitabine-based chemotherapy. The drug helps in
boosting the body’s own immune system to fight cancer cells.
Segment Analysis
The global pancreatic cancer
therapeutics and diagnostic market is segmented into diagnostics and
therapeutics. The diagnostics segment dominates the market and is expected to
continue its dominance over the forecast period. Early and accurate diagnosis
plays a crucial role in treating pancreatic cancer as it has a very low
survival rate when diagnosed at later stages. Diagnostic imaging techniques
such as computerized tomography (CT) scans, magnetic resonance imaging (MRI),
endoscopic ultrasound (EUS), and positron emission tomography (PET) scans are
widely used for pancreatic cancer screening and diagnosis.
Key Takeaways
The Global
Pancreatic Cancer Therapeutics and Diagnostic Market Size is expected
to witness high growth, exhibiting CAGR
of 7.4% over the forecast period, due to increasing incidence of pancreatic
cancer worldwide.
Regional analysis
North America dominates the
global market and is expected to continue its dominance in the coming years.
This is attributed to advanced healthcare infrastructure, availability of
skilled professionals, and presence of key market players in the region. Asia
Pacific is expected to exhibit the highest growth rate during the forecast
period owing to increasing awareness regarding pancreatic cancer diagnosis and
treatment.
Key players
Key players operating in the
pancreatic cancer therapeutics and diagnostic market are F Hoffmann-La Roche
AG, Merck KgaA, Apexigen Inc., Immunovia AB, Viatris Inc., Amgen Inc.,
AstraZeneca PLC, Bristol-Myers Squibb, Novartis AG, Pfizer Inc., Myriad
Genetics Inc., Canon Medical Systems Corporation, FUJIFILM Holdings
Corporation, Boston Scientific Corporation, and Rafael Holdings Inc. (Rafael
Pharmaceuticals). These players are focusing on developing novel drugs and
diagnostic techniques to improve treatment outcomes of pancreatic cancer
patients.
Get More Insights Here
https://www.newswirestats.com/pancreatic-cancer-therapeutics-and-diagnostic-market/
Comments
Post a Comment